The $15M prepayment condition to the Perceptive Sixth Amendment must be satisfied by November 30, 2026. Monitor for a subsequent 8-K confirming the prepayment and covenant amendment effectiveness, which would remove the going concern risk. The 20.4% discount and the company's history of losses suggest continued equity overhang.
STIM drugs
STIM drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 12 $1.43entry
- T+1 · 4d ago −2.80%α −2.43% · $1.39
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Neuronetics closed a $30M underwritten public offering of 18.75M shares at $1.60/share, a 20.4% discount to the prior close. Net proceeds of ~$27.7M will partially repay the $65M Perceptive credit facility (11.5% interest) and fund general corporate purposes. The offering is tied to a November 5 amendment requiring a $15M prepayment by November 30 to avoid automatic termination and resolve the going concern warning.
Key Financial Metrics
Key Facts
- 18,750,000 shares sold at $1.60/share, a 20.4% discount to the $2.01 last sale price
- Underwriters have a 30-day option for up to 2,812,500 additional shares
- Net proceeds estimated at ~$27.7M (or ~$31.9M if option exercised in full)
- Proceeds will partially repay the $65M Perceptive credit facility (11.5% interest) and fund general corporate purposes
- Amendment No. 6 to the Perceptive Facility requires a $15M prepayment by November 30, 2026 to avoid automatic termination
- Company has a going concern warning tied to trailing twelve-month revenue projections
- Offering priced on November 10, 2026 and closed on November 12, 2026
Financial Impact
$30M gross proceeds, ~$27.7M net proceeds; 18.75M new shares represent approximately 12% dilution based on pre-offering market cap of $156M
Risk Factors
- If the $15M prepayment condition is not satisfied by November 30, the Perceptive Sixth Amendment terminates automatically, leaving the original restrictive covenants in place and the going concern risk unresolved
- Dilution of approximately 12% from the offering may pressure the stock price
- Company has a history of losses and relies on the sale and usage of its NeuroStar Advanced Therapy System to generate revenues
- High debt service costs (11.5% interest on $65M facility) may constrain cash flow
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-457099 |
| Document: d428716d8k.htm | 0001193125-26-457099 |
| Document: d428716dex51.htm | 0001193125-26-457099 |
| Document: d428716dex991.htm | 0001193125-26-457099 |
| Document: d428716dex992.htm | 0001193125-26-457099 |
| Document: 0001193125-26-457099-index-headers.html | 0001193125-26-457099 |
| Document: 0001193125-26-457099-index.html | 0001193125-26-457099 |
| Document: 0001193125-26-457099.txt | 0001193125-26-457099 |
Track record
30 reports on STIM
6 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +11.73% at T+1 after the Nov 10, 2026 report. 7 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13D/A Neutral 4/10 Entry price pending
- Nov 16, 2026today SC 13D/A Bearish 6/10 Entry price pending
- Nov 12, 20264d ago 8-K/A Bearish 5/10 Entry $1.39 to $1.25 Now $1.25 +10.07% ▲ +10.07% +8.16% vs SPY
- Nov 12, 20264d ago 8-K Bearish 6/10 Viewing Entry $1.43 to $1.39 Now $1.25 +12.59% ▲ +2.80% +2.43% vs SPY
- Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $1.43 to $1.39 Now $1.25 +12.59% ▲ +2.80% +2.43% vs SPY
- Nov 10, 20265d ago Press Release Bearish 6/10 Entry $1.62 to $1.43 Now $1.25 +22.84% ▲ +11.73% +11.37% vs SPY
- Nov 10, 20266d ago 424B5 Bearish 6/10 Entry $1.62 to $1.43 Now $1.25 +22.84% ▲ +11.73% +11.37% vs SPY
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.62 to $1.43 Now $1.25 −22.84% ▼ −11.73% −11.37% vs SPY
- Nov 10, 20266d ago Press Release Bearish 6/10 Entry $1.62 to $1.43 Now $1.25 +22.84% ▲ +11.73% +11.37% vs SPY
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $2.01 to $1.62 Now $1.25 −37.81% ▼ −19.40% −20.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers